The sell-off was unusually severe for a biotech company that hasn’t failed a clinical trial or been involved in some kind of scandal. I thought about buying some, but didn’t; there are a lot of other compelling buys around.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”